Hematological malignancies in Cameroonian women with cancer attending a health facility: High prevalence and implications for follow up

Paper Details

Research Paper 01/07/2016
Views (265) Download (4)

Hematological malignancies in Cameroonian women with cancer attending a health facility: High prevalence and implications for follow up

Idriss Lemouchele Ntatou, Martin Luther Mogtomo Koanga, Cecile Okalla Ebongue, Esther Dina Bell, Nkeumacha Ida Patrick, Loick Pradel Foko Kojom, Elisée Enyegue Embolo, Martin Biwole Essomba, Eliane Okoubalimba Assokom, Anne Marie Maïsson, Annie Rosalie Ngane Ngono, Albert SoneMoelle
Int. J. Biosci.9( 1), 72-82, July 2016.
Certificate: IJB 2016 [Generate Certificate]


This study aimed at determining the prevalence of hematological malignancies in cancer patients and discussing about implications for follow-up. A five-month hospital-based cross sectional study was carried out in 2015 in the town of Douala, Cameroon. Personal data were documented and 4 mL of venous blood was collected for full blood count. A total of 172 women were enrolled and divided into three groups: 74 in the cervical cancer group (CCG), 69 in the breast cancer group (BCG) and 29 in the control group (CG). Radiotherapy associated with chemotherapy was the most used therapeutic option (> 50.0 %). The prevalence of hematological disorders was 86.5 %, 75.4 % and 51.7 % in CCG, BCG and CG respectively (χ2 = 13.909; p-value < 0.0001). Anemia was the most observed disorder and accounted for more than 40 % of all disorders observed in the three groups. Cancer and its therapy have negatively affected each of the blood parameters analyzed (p-value < 0.05).Our findings suggest the need for cautious and adjusted follow-up of Cameroonian cancer patients through surrogate markers such as blood parameters in order to enhance their life expectancy.


Alberts B, Alexander J, Julian L, Martin R, Keith R, Peter W. 2002. Molecular biology of the cell, 4th. New York, USA: Garland Science, p. 1616 .

Butel JS. 2000. Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. Carcinogenesis 21(3), 405-426. http://dx.doi.org/10.1093/carcin/21.3.405

Erkurt MA, Kaya E, Berber I, Koroglua M, Kuku I. 2012. Thrombocytopenia in Adults: Review Article. Journal of Hematology 1(2-3), 44-53. http://dx.doi.org/10.4021/jh28w

Frede S, Fandrey J, Pagel H, Hellwig T, Jelkmann W. 1997. Erythropoietin gene expression is suppressed after lipopolysaccharide or interleukin-1 beta injections in rats. American Journal of Physiology 273, R1067-1071.

Gauer RL, Braun MM. 2012. Thrombocytopenia. American Family Physician 85(6), 612-622.

Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. 2010. Diabetes and cancer. Diabetes Care 33, 1674-1675. http://dx.doi.org/10.2337/dc10-0666

GLOBOCAN. 2012. Statistics on cancer. www.globocan.iarc.fr

Griffiths AJF, David TS. 2002. Introduction à l’analyse génétique; traduction de la 7e édition américaine par Chrystelle Sanlaville ; révision scientifique de Denise Aragnol et Dominique Charmot, 3e éd. Paris, Brussels, Belgium: De Boeck., 860 P.

Hanahan D, Weinberg RA. 2000. The Hallmarks of Cancer. Cell 100, 57-70. http://dx.doi.org/10.1016/S0092-8674(00)81683-9

Kemfang Ngowa JD, Yomi J, Kasia JM, Mawamba Y, Ekortarh AC, Vlastos G. 2011. Breast cancer profile in a group of patients followed up at the Radiation Therapy Unit of the Yaounde General Hospital, Cameroon [serial online]. Obstetrics and Gynecology International 2011, ID143506: http://dx.doi.org/10.1155/2011/143506.

Koanga Mogtomo ML, GouabeMalieugoue LC, Djiepgang C, Wankam M, Moune A, NgonoNgane A. 2009. Incidence of cervical disease associated to HPV in human immunodeficiency infected women under highly active antiretroviral therapy. Infectious Agents and Cancer 4, 9. http://dx.doi.org/10.1186/1750-9378-4-9

Koanga Mogtomo ML, NgonoNgane A, Djiakam Nganwa G, Wankam M, Brulet Epaka C, Amvam Zollo PH. 2014. Association of Cervical Inflammation and Cervical Abnormalities in Women Infected with Herpes Simplex Virus Type 2. International Journal of Tropical Medicine and Public Health 1(1), 1-4. http://dx.doi.org/171350/ijtmph

Koanga Martin LM, Embolo EE, Eboumbou CE, Olemba C, Eloumou EL, Assam Assam JP, Mouelle Albert S. 2015. Blood tissue cytological status  of  prognosis  and  predictive  markers in  the natural history of solid cancer development. Journal of Clinical Immunology and Immunopathology Research 6(1), 1-8. http://dx.doi.org/10.5897/JCIIR2014.0068.

Kolahi S, Farzin H, Khoshbaten M. 2008. Hypochromic Microcytic Anemia in North western Of Tabriz, Iran. European Journal Genetic Medicine 5 (3), 178-180.

Mach-Pascual S, Darbellay R, Pilotto PA, Beris P. 1996. Investigation of microcytosis: A comprehensive approach. European Journal of Haematology 57, 54-61. http://dx.doi.org/10.1111/j.16000609.1996.tb00490.x

Means RT Jr. 2004. Hepcidin and anaemia. Blood Review 18, 219-225. http://dx.doi.org/10.1016/S0268-960X(03)00066-3

Mercadante S, Gebbia V, Marrazzo A, Filosto S. 2000. Anaemia in cancer: pathophysiology and treatment. Cancer Treatment Reviews 26, 303–311. http://dx.doi.org/10.1053/ctrv.2000.0181

Orang-Ojong BB, Munyangaju JE, Shang WM, Lin M, Guan WF, Foukunang C, Zhu Y. 2013. Impact of natural resources and research on cancer treatment and prevention: A perspective from Cameroon (Review). Molecular and Clinical Oncology 1, 610-620. http://dx.doi.org/10.3892/mco.2013.132

Price AJ, Ndom P, Atenguena E, MambouNouemssi JP, Ryder RW. 2012. Cancer Care Challenges in Developing Countries. Cancer 118, 3627-3635. http://dx.doi.org/10.1002/cncr.26681

Rigal OBE, Druesne L, Chassagne L. 2006. Épidémiologie: cancer et sujet âgé. Psychooncology 3, 141-146.

Rochet NM, MarkovicSvetomir N, Porrata LF. 2012.  The  Role  of  Complete  Blood  Cell  Count  in Prognosis-Watch this Space! Oncology & Hematology Review 8(1), 76-82. http://doi.org/10.17925/OHR.2012.08.1.76

Sapolnik R. 2003. Intensive care therapy for cancer patients. Journal of Pediatrics (Rio de Janeiro) 79 (Suppl 2), S231-S42.

Tavares-Murta BM, Murta EFC. 2008. Systemic leukocyte alterations in cancer and their relation to prognosis. The Open Cancer Journal 2, 53-58.

Tefferi A, Hanson CA, Inwards DJ. 2005. How to Interpret and Pursue an Abnormal Complete Blood Cell Count in Adults. Mayo Clinical Proceedings 80 (7), 923-936. http://dx.doi.org/10.4065/80.7.923

Thomas G. 2001. The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience. Seminary Oncology 28(Suppl.8), 60–65. http://dx.doi.org/10.1016/S0093-7754(01)90215-5

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. 2015. Global Cancer Statistics, 2012. A Cancer Journal for Clinicians 65, 85-108. http://dx.doi.org/10.3322/caac.21262

Van Belle SJP. 2004. What is the value of hemoglobin as a prognostic and predictive factor in cancer ? EJC Supplements 2(2), 11–19. http://dx.doi.org/10.1016/S1359-6349(03)00103-4

WHO. 2014. Body mass index. 20 avenue Appia, 1211 Geneva 27, Switzerland: World Health Organization: http://www.globocan.iarc.fr